Gadi, Deepti
Griffith, Alec http://orcid.org/0000-0002-4289-3017
Tyekucheva, Svitlana http://orcid.org/0000-0002-3119-6507
Wang, Zixu
Rai, Vanessa
Vartanov, Alexander
Thrash, Emily http://orcid.org/0000-0002-3423-0336
Fernandes, Stacey M.
Lehmberg, Timothy Z.
Lee, Brandon
Martindale, Stephen P.
Machado, John-Hanson http://orcid.org/0000-0003-0477-3476
Odejide, Oreofe
Armand, Philippe http://orcid.org/0000-0001-6098-1603
Fisher, David C.
Arnason, Jon
Davids, Matthew S. http://orcid.org/0000-0003-4529-2003
Lederer, James A.
Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30AR070253, P30AR069625, R01 CA 213442)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Verastem Oncology
Article History
Received: 14 April 2021
Revised: 22 September 2021
Accepted: 27 September 2021
First Online: 6 November 2021
Competing interests
: ET has received travel expenses and honorariums from Fluidigm and is a current employee of Fluidigm. TZL is a current employee of Casma Therapeutics. PA has served as a consultant for Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, GenMab, C4, Enterome, Regeneron, Epizyme, Astra Zeneca, and Genentech; received research funding from Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech, IGM, and Kite; and received honoraria from Merck and BMS. DCF served on the advisory board for Kyowa Kirin. JA served on the advisory boards for Regeneron and BMS/Celgene. MSD has received research funding from AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem; has served on the advisory board for AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene, Eli Lilly, Janssen, Pharmacyclics, Takeda, and TG Therapeutics; has served as a consultant for AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech, Janssen, Merck, Pharmacyclics, Research to Practice, Syros Pharmaceuticals, TG Therapeutics, Verastem, and Zentalis. JAL consults for Alloplex Biotherapeutics. JRB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Beigene, Bristol Myers Squibb/Juno/Celgene, Catapult, Dynamo, Eli Lilly, Genentech/Roche, Gilead, Janssen, Kite, Loxo, MEI Pharma, Morphosys AG, Nextcea, Novartis, Octapharma, Rigel, Pfizer, Pharmacyclics, Redx, Sun, Sunesis, TG Therapeutics, Verastem; received honoraria from Janssen and Teva; received research funding from Gilead, Loxo/Lilly, Sun and Verastem/SecuraBio, and TG Therapeutics; and served on data safety monitoring committees for Morphosys and Invectys. DG, AG, ST, ZW, VR, AV, SMF, BL, SPM, JHM and OO have no COI to disclose.